Recent findings from a head-to-head clinical trial reveal that the weight loss drug Zepbound outperformed its competitor, Wegovy. Participants using Zepbound lost an average of 50 pounds, equating to 20% of their body weight, compared to a 33-pound average loss or nearly 14% of body weight for those on Wegovy.
The study involved 751 adults who were overweight or obese and had additional health conditions such as high blood pressure or high cholesterol, though they did not have diabetes. The participants were randomly assigned to take either Zepbound or Wegovy for a duration of 72 weeks.
Interestingly, while Zepbound showed a higher average weight loss, the majority of participants using both drugs lost less than 25% of their total body weight. Specifically, around 32% of those using Zepbound and 16% of those on Wegovy experienced this lesser degree of weight loss.
Zepbound’s active ingredient, tirzepatide, is also found in the diabetes medication Mounjaro, whereas Wegovy, alongside its diabetes-related counterpart Ozempic, is based on the active ingredient semaglutide.
The study was financed by Eli Lilly, the manufacturer of Zepbound, which made the results known through a press release aimed at investors. It’s important to note that these findings have not yet been published in a peer-reviewed medical journal, and additional details are expected in the future.
The results are consistent with earlier analyses suggesting that Zepbound could offer superior weight loss benefits compared to its competitors, even before rigorous clinical trials were conducted. The full results will be shared at an upcoming medical conference next year.
Source: WebMD
